MTOR and ovarian carcinoma: However, it is known that PI3K/AKT activation contributes to a reduced response to chemotherapy in ovarian cancer [144] and that modulation of the PI3K/AKT/mTOR pathway is suitable for overcoming resistance to chemotherapy [132].